CYP2C19 and Clopidogrel: A Pharmacogenomics Case Study
The antiplatelet drug clopidogrel (Plavix) requires metabolic activation by CYP2C19. Poor metabolizers get no benefit from standard dosing.
Category: Research · By GenomeNarrator Team · 6 min read
Read the full article at https://genomenarrator.com/blog/cyp2c19-and-clopidogrel-a-pharmacogenomics-case-study. Return to all genomics articles or GenomeNarrator home.